[Form 4] Dolby Laboratories, Inc. Insider Trading Activity

Dolby Laboratories SVP, Entertainment John D. Couling reported multiple stock transactions in Dolby Laboratories, Inc. Class A Common Stock.

Rhea-AI Filing Summary

Dolby Laboratories SVP, Entertainment John D. Couling reported multiple stock transactions in Dolby Laboratories, Inc. Class A Common Stock. On May 4–5, 2026, he sold a total of 12,354 shares in open-market transactions at weighted average prices around $57–$58 per share.

On the same date, he also exercised employee stock options covering 7,666 shares at an exercise price of $45.50 per share. A footnote states that shares held following these transactions include 55,114 shares underlying restricted stock units that remain subject to forfeiture until they vest.

The sales were executed in multiple trades within disclosed price ranges and were carried out under a Rule 10b5-1 trading plan adopted on February 3, 2026, indicating they were pre-scheduled rather than discretionary market-timing decisions.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Couling John D

Role SVP, Entertainment

Sold 12,354 shs ($715K)

Approx. gross sale proceeds $715K

Approx. exercise cost $349K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Buy)	7,666	$0.00	$0.00
Exercise	Class A Common Stock	7,666	$45.50	$349K
Sale	Class A Common Stock	6,928	$57.4708	$398K
Sale	Class A Common Stock	738	$58.3354	$43K
Sale	Class A Common Stock	4,688	$58.465	$274K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 38,334 contracts (Direct); Class A Common Stock — 118,353 shares (Direct)

Footnotes (4)

1. F1. Shares held following the reported transactions include 55,114 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest.
2. F2. The shares were sold in multiple transactions at prices ranging from $57.16 to $58.05 , inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The shares were sold pursuant to a 10b5-1 trading plan adopted on February 3, 2026.
3. F3. The shares were sold in multiple transactions at prices ranging from $58.195 to $58.36, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The shares were sold pursuant to a 10b5-1 trading plan adopted on February 3, 2026.
4. F4. This option was granted for a total of 46,000 shares of Class A Common Stock. The option exercised in this transation was fully vested and exercisable as of the transaction date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Dolby (DLB) SVP John D. Couling report?

John D. Couling reported selling 12,354 shares of Dolby Class A Common Stock and exercising employee stock options for 7,666 shares at $45.50 per share. The transactions occurred on May 4–5, 2026, and were disclosed in a Form 4 insider filing.

At what prices did Dolby (DLB) SVP John D. Couling sell his shares?

Couling’s sales occurred in multiple trades with weighted average prices around $57–$58 per share. Footnotes state price ranges from $57.16 to $58.36, with exact trade-level details available on request to regulators, the issuer, or any Dolby security holder.

Were John D. Couling’s Dolby (DLB) share sales made under a 10b5-1 plan?

Yes. The Form 4 footnotes state the Dolby SVP’s share sales were made under a Rule 10b5-1 trading plan adopted on February 3, 2026. Such plans pre-schedule trades, meaning the timing of these sales was arranged in advance rather than decided opportunistically.

What stock options did Dolby (DLB) SVP John D. Couling exercise?

Couling exercised employee stock options covering 7,666 shares of Dolby Class A Common Stock at an exercise price of $45.50 per share. A footnote notes the option was originally granted for 46,000 shares and was fully vested and exercisable on the transaction date.

How many Dolby (DLB) restricted stock units does John D. Couling hold after these trades?

A footnote explains that shares held following the reported transactions include 55,114 shares of Dolby Class A Common Stock underlying restricted stock units. These restricted stock units remain subject to forfeiture until they vest, so they are not yet fully-owned unrestricted shares.

What is the net share impact of John D. Couling’s recent Dolby (DLB) transactions?

Across the reported transactions, Couling sold 12,354 shares of Dolby Class A Common Stock and exercised stock options for 7,666 shares. The transaction summary shows a net-sell direction, reflecting more shares sold than acquired through the option exercise in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 05:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Couling John D

(Last) (First) (Middle)

C/O DOLBY LABORATORIES, INC.

1275 MARKET STREET

(Street)

SAN FRANCISCO CALIFORNIA 94103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dolby Laboratories, Inc. [ DLB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Entertainment

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/04/2026		S		4,688	D	$58.465	118,353(1)	D
Class A Common Stock	05/05/2026		M		7,666	A	$45.5	126,019(1)	D
Class A Common Stock	05/05/2026		S		6,928	D	$57.4708(2)	119,091(1)	D
Class A Common Stock	05/05/2026		S		738	D	$58.3354(3)	118,353(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$45.5	05/05/2026		M			7,666	(4)	12/15/2026	Class A Common Stock	7,666	$0	38,334	D

Explanation of Responses:

1. Shares held following the reported transactions include 55,114 shares of Class A common stock underlying restricted stock units, which are subject to forfeiture until they vest.

2. The shares were sold in multiple transactions at prices ranging from $57.16 to $58.05 , inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The shares were sold pursuant to a 10b5-1 trading plan adopted on February 3, 2026.

3. The shares were sold in multiple transactions at prices ranging from $58.195 to $58.36, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The shares were sold pursuant to a 10b5-1 trading plan adopted on February 3, 2026.

4. This option was granted for a total of 46,000 shares of Class A Common Stock. The option exercised in this transation was fully vested and exercisable as of the transaction date.

	/s/ Daniel Rodriguez as Attorney-in-Fact for John Couling	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)